AAAAAA
Results:
1-13
|
Results: 13
Authors:
Mozsik, G
Karadi, O
Kiraly, A
Debreceni, A
Figler, M
Nagy, L
Par, A
Par, G
Suto, G
Vincze, A
Citation: G. Mozsik et al., The key-role of vagal nerve and adrenals in the cytoprotection and generalgastric mucosal integrity, J PHYSL-PAR, 95(1-6), 2001, pp. 229-237
Authors:
Rumi, G
Matus, Z
Toth, G
Par, A
Nagy, Z
Vincze, A
Rumi, G
Mozsik, G
Citation: G. Rumi et al., Changes of serum carotenoids in patients with esophageal, gastric, hepatocellular, pancreatic and colorectal cancer, J PHYSL-PAR, 95(1-6), 2001, pp. 239-242
Authors:
Par, A
Telegdy, L
Dalmi, L
Muller, E
Citation: A. Par et al., Therapy for chronic hepatitis C, J PHYSL-PAR, 95(1-6), 2001, pp. 399-405
Authors:
Gasztonyi, B
Par, A
Battyany, I
Hegedus, G
Molnar, TF
Horvath, L
Mozsik, G
Citation: B. Gasztonyi et al., Multimodality treatment resulting in long-term survival in hepatocellular carcinoma, J PHYSL-PAR, 95(1-6), 2001, pp. 413-416
Authors:
Nagy, Z
Nagy, A
Karadi, O
Figler, M
Rumi, G
Suto, G
Vincze, A
Par, A
Mozsik, G
Citation: Z. Nagy et al., Prevalence of the factor V Leiden mutation in human inflammatory bowel disease with different activity, J PHYSL-PAR, 95(1-6), 2001, pp. 483-487
Authors:
Mozsik, G
Nagy, Z
Nagy, A
Rumi, G
Karadi, O
Czimmer, J
Matus, Z
Toth, G
Par, A
Citation: G. Mozsik et al., Leiden mutation (as genetic) and environmental (retinoids) sequences in the acute and chronic inflammatory and premalignant colon disease in human gastrointestinal tract, J PHYSL-PAR, 95(1-6), 2001, pp. 489-494
Authors:
Mozsik, G
Bodis, B
Figler, M
Kiraly, A
Karadi, O
Par, A
Rumi, G
Suto, G
Toth, G
Vincze, A
Citation: G. Mozsik et al., Mechanisms of action of retinoids in gastrointestinal mucosal protection in animals, human healthy subjects and patients, LIFE SCI, 69(25-26), 2001, pp. 3103-3112
Authors:
Biro, L
Varga, L
Par, A
Nemesanszky, E
Csepregi, A
Telegdy, L
Ibranyi, E
David, K
Horvath, G
Szentgyorgyi, L
Nagy, I
Dalmi, L
Abonyi, M
Fust, G
Horanyi, M
Citation: L. Biro et al., Changes in the acute phase complement component and IL-6 levels in patients with chronic hepatitis C receiving interferon alpha-2b, IMMUNOL LET, 72(2), 2000, pp. 69-74
Authors:
Biro, L
Varga, L
Par, A
Nemesanszky, E
Telegdy, L
Ibranyi, E
David, K
Horvath, G
Szentgyorgyi, L
Nagy, I
Dalmi, L
Abonyi, M
Fust, G
Horanyi, M
Csepregi, A
Citation: L. Biro et al., C5b-9 and interleukin-6 in chronic hepatitis C - Surrogate markers predicting short-term response to interferon alpha-2b, SC J GASTR, 35(10), 2000, pp. 1092-1096
Authors:
Gasztonyi, B
Par, A
Szomor, A
Battyany, I
Nagy, A
Kereskai, L
Losonczy, H
Mozsik, G
Citation: B. Gasztonyi et al., Hepatitis C virus infection associated with B-cell non-Hodgkin's lymphoma in Hungarian patients, BR J HAEM, 110(2), 2000, pp. 497-498
Authors:
Nagy, Z
Nagy, A
Karadi, O
Par, A
Mozsik, G
Citation: Z. Nagy et al., The high prevalence of the factor V Leiden mutation in central European inflammatory bowel disease patients, AM J GASTRO, 95(10), 2000, pp. 3013-3014
Authors:
Farkas, H
Csepregi, A
Nemesanszky, E
Par, A
Gyeney, L
Varga, L
Fust, G
Citation: H. Farkas et al., Acquired angioedema associated with chronic hepatitis C, J ALLERG CL, 103(4), 1999, pp. 711-712
Authors:
Par, A
Gervain, J
Gogl, A
Citation: A. Par et al., Hepatitis c virus infection: Pathogenesis, diagnosis and treatment, SC J GASTR, 33, 1998, pp. 107-114
Risultati:
1-13
|